Cyclerion Therapeutics Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Cyclerion Therapeutics.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 26.8% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Cyclerion stock tanks 32% on workforce reduction, clinical development refocus
Oct 06We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate
Aug 09
We're Keeping An Eye On Cyclerion Therapeutics' (NASDAQ:CYCN) Cash Burn Rate
Mar 03Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders
Oct 26Cyclerion Therapeutics: Insiders Buying With No Clinical Data Due Until YE 2021
Jun 21Cyclerion climbs on a series of insider purchases
Jun 08Cyclerion updates on clinical trial progress at webinar
Apr 28Who Has Been Buying Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Shares?
Mar 09What Kind Of Shareholders Hold The Majority In Cyclerion Therapeutics, Inc.'s (NASDAQ:CYCN) Shares?
Jan 28
Cyclerion Therapeutics +10.5% after prelim reports
Jan 13Cyclerion Therapeutics announces promotions
Dec 21Can You Imagine How Cyclerion Therapeutics' (NASDAQ:CYCN) Shareholders Feel About The 40% Share Price Increase?
Dec 20Cyclerion Therapeutics reports Q3 results
Nov 05In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cyclerion Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 9/30/2024 | 0 | -5 | -6 | -6 | N/A |
| 6/30/2024 | N/A | -10 | -11 | -11 | N/A |
| 3/31/2024 | N/A | -11 | -17 | -17 | N/A |
| 12/31/2023 | N/A | -13 | -21 | -21 | N/A |
| 9/30/2023 | N/A | -15 | -27 | -27 | N/A |
| 6/30/2023 | -1 | 3 | -30 | -30 | N/A |
| 3/31/2023 | 0 | -8 | -34 | -34 | N/A |
| 12/31/2022 | 0 | -18 | -41 | -41 | N/A |
| 9/30/2022 | 1 | -25 | -42 | -42 | N/A |
| 6/30/2022 | 2 | -48 | -40 | -40 | N/A |
| 3/31/2022 | 5 | -51 | -35 | -35 | N/A |
| 12/31/2021 | 4 | -52 | -37 | -37 | N/A |
| 9/30/2021 | 4 | -60 | -42 | -42 | N/A |
| 6/30/2021 | 4 | -68 | -49 | -49 | N/A |
| 3/31/2021 | 1 | -71 | -58 | -58 | N/A |
| 12/31/2020 | 2 | -78 | -74 | -72 | N/A |
| 9/30/2020 | 4 | -85 | -82 | -81 | N/A |
| 6/30/2020 | 5 | -93 | -92 | -89 | N/A |
| 3/31/2020 | 6 | -106 | -104 | -97 | N/A |
| 12/31/2019 | 5 | -123 | -109 | -102 | N/A |
| 9/30/2019 | 3 | -128 | -112 | -103 | N/A |
| 6/30/2019 | 2 | -130 | -114 | -105 | N/A |
| 3/31/2019 | N/A | -127 | -110 | -105 | N/A |
| 12/31/2018 | N/A | -115 | -101 | -98 | N/A |
| 9/30/2018 | N/A | -112 | -102 | -100 | N/A |
| 6/30/2018 | N/A | -108 | N/A | -95 | N/A |
| 3/31/2018 | N/A | -99 | N/A | -90 | N/A |
| 12/31/2017 | N/A | -94 | N/A | -81 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if CYCN's forecast earnings growth is above the savings rate (2.6%).
Earnings vs Market: Insufficient data to determine if CYCN's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if CYCN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if CYCN's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if CYCN's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CYCN's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 14:29 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Cyclerion Therapeutics, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| Martin Auster | Credit Suisse |
| Joon So Lee | Truist Securities |